Abstract: The present invention relates to a method for creating two- and three-dimensional arrays. Plates of sample materials are stacked to create primary stacks. Primary stacks are sliced to form combs. Combs are stacked to form secondary stacks. Secondary stacks are sliced to form tertiary plates or two-dimensional arrays. Tertiary plates can be stacked to form three-dimensional arrays. The two- and three-dimensional arrays can be used in large-scale parallel processing of samples, pattern printing, tissue engineering, microfluidics, microelectronics, and microconstruction.

Abstract: Methods and apparatus are provided for calibrating a pipeline analog-to-digital converter including one or more serially connected analog-to-digital pipeline stages and a back-end analog-to-digital converter.

Abstract: A method is provided for reducing near-field radiation and specific absorption rate (SAR) values in a communications device. The communications device includes a multimode antenna structure transmitting and receiving electromagnetic signals and circuitry for processing signals communicated to and from the antenna structure. The method includes adjusting the relative phase between signals fed to neighboring antenna ports of the antenna structure such that a signal fed to the one antenna port has a different phase than a signal fed to the neighboring antenna port to provide antenna pattern control and to increase gain in a selected direction toward a receive point.

Abstract: A variable gain amplifier (VGA) disclosed herein includes an input current connector, an output current connector, a gain adjustment connector, scaled current mirrors copying the input current, means for steering the copied currents either to the current output or to another appropriate location based on the signal present at the gain adjustment connector.

Abstract: Aspects of the invention relate to an applicator, and methods of use thereof, which can house multiple component formulations in separate material receptacles, which components can then be easily combined at the time of use without assembly by the user. In certain embodiments, a device of the invention can be used for, but is not limited to, applying hydrogel formulations to dura mater, abdominal tissue in hernia repair, tissues near the spine, lung tissue, intestinal tissue, or any of the internal tissues. In certain embodiments, a device of the invention can be configured to apply a spray or a stream of a liquid formulation to a surface. In certain embodiments, a device of the invention can be configured to deliver the formulation through an endoscope or laparoscope.

Abstract: Methods for the preparation of the ? isomer of a 9-deazapurine derivatives using benzyl protecting groups as the protecting groups for the 2 and 3 hydroxyl groups in ribose are provided.

Abstract: A method of performing a chemical reaction includes reacting a compound selected from the group consisting of an organohalide and an organo-pseudohalide, and a protected organoboronic acid represented by formula (I) in a reaction mixture: R1—B-T??(I); where R1 represents an organic group, T represents a conformationally rigid protecting group, and B represents boron having sp3 hybridization. When unprotected, the corresponding organoboronic acid is unstable by the boronic acid neat stability test. The reaction mixture further includes a base having a pKB of at least 1 and a palladium catalyst. The method further includes forming a cross-coupled product in the reaction mixture.

Abstract: Methods and systems for generating bremsstrahlung with enhanced photon flux in a narrow cone at forward angles utilize a thin target of a high-Z material such as gold as radiator, supported on a tube of a low-Z material such as titanium, which tube contains a circulating fluid such as water which acts as a coolant and also may absorb the incident electron beam.

Abstract: A control apparatus is provided for use in an electric vehicle having a throttle input device. The throttle input device is operable by a rider for generating a throttle signal for controlling the speed of the electric vehicle. The control apparatus, which adjusts the throttle signal, includes a rider input mechanism and a control device. The rider input mechanism can be manipulated by the rider to provide a given input. The control device is coupled to the rider input mechanism and to the output of the throttle input device. The control device adjusts the throttle signal based on the given input provided by the rider input mechanism.

Abstract: Novel curcumin-analog compounds are disclosed that are antioxidants useful in inhibition of pro-inflammation, angiogenic, and vascular permeability factors and elimination of reactive oxygen species. The curcumin compounds specifically inhibit VEGF and are useful in treating various diseases that are mediated through the oxidative stress pathway, including those that are characterized by inflammation, angiogenesis, or vascular leakage.

Abstract: Devices and methods are disclosed for implanting, positioning, removing, replacing and operating intra-aortic balloon pumps.

Abstract: LSD1, a homolog of nuclear amine oxidases, functions as a histone demethylase and transcriptional co-repressor. LSD1 specifically demethylates histone H3 lysine 4, which is linked to active transcription. Lysine demethylation occurs via an oxidation reaction that generates formaldehyde. Importantly, RNAi inhibition of LSD1 causes an increase in H3 lysine 4 methylation and concomitant de-repression of target genes, suggesting that LSD1 represses transcription via histone demethylation. The results thus identify a histone demethylase conserved from S. pombe to human and reveal dynamic regulation of histone methylation by both histone methylases and demethylases.

Abstract: Certain aspects of the invention relate to an applicator, and methods of use thereof, which can house multiple component formulations in separate material receptacles, which can then be easily reconstituted at time of use without any assembly by the user. A device of the invention can be used for, but is not limited to, applying hydrogel formulations to dura mater, abdominal tissue in hernia repair, tissues near the spine, lung tissue, intestinal tissue, and any of the internal tissues. A device of the invention can be configured to apply a spray or a stream of liquid formulation onto a surface to be treated. A device of the invention can be configured to deliver the formulation through an endoscope or laparoscope.

Abstract: Devices for treating stress incontinence, having a horizontal proximal portion supported on the pubococcygeus muscle and a distal portion extending downward and away from the proximal portion at an angle approximating the vagina in an erect female as it passes down and between the anterior segments of the pubococcygeus. The distal portion may terminate with a protrusion that is positioned to provide midurethral support, thereby preserving the urethrovesical angle.

Abstract: Devices and methods are disclosed for implanting, positioning, removing, replacing and operating intra-aortic balloon pumps.

Abstract: The present invention provides novel stabilized crosslinked compounds having secondary structure motifs, libraries of these novel compounds, and methods for the synthesis of these compounds libraries thereof. The synthesis of these novel stabilized compounds involves (1) synthesizing a peptide from a selected number of natural or non-natural amino acids, wherein said peptide comprises at least two moieties capable of undergoing reaction to promote carbon-carbon bond formation; and (2) contacting said peptide with a reagent to generate at least one crosslinker and to effect stabilization of a secondary structure motif. The present invention, in a preferred embodiment, provides stabilized p53 donor helical peptides. Additionally, the present invention provides methods for disrupting the p53/MDM2 binding interaction comprising (1) providing a crosslinked stabilized ?-helical structure; and (2) contacting said crosslinked stabilized ?-helical structure with MDM2.

Abstract: The present invention provides methods for modification and regulation of glucagon-like peptide 1 (GLP-1) metabolism by administering therapeutically effective amounts of an inhibitor of dipeptidylpeptidase IV (DPIV) or a pharmaceutically acceptable salt thereof, where the inhibitor has a Ki for inhibition of DPIV of 10 nM or less; and the inhibitor is administered in an amount sufficient to inhibit DPIV proteolysis of GLP-1 but not sufficient to suppress the immune system of the animal.

Abstract: A protected organoboronic acid includes a boron having an sp3 hybridization, a conformationally rigid protecting group bonded to the boron, and an organic group bonded to the boron through a boron-carbon bond. A method of performing a chemical reaction includes contacting a protected organoboronic acid with a reagent, the protected organoboronic acid including a boron having an sp3 hybridization, a conformationally rigid protecting group bonded to the boron, and an organic group bonded to the boron through a boron-carbon bond. The organic group is chemically transformed, and the boron is not chemically transformed.

Abstract: Polypeptide analogs of the invention that include a) a base amino acid sequence at least 80% identical to one of a GLP-1 fragment; and b) amino acid residues attached to the carboxy terminus of the base amino acid sequence, where the analogs have GLP-1-like activity of longer duration than native GLP-1 and/or the GLP-1 receptor has a greater affinity for the analogs than native GLP-1. Other polypeptide analogs of the invention include a) a base amino acid sequence at least 50% identical to a GLP-1 fragment in which the amino acid residue in the base amino acid sequence corresponding to the P?1 residue of GLP-1 is an amino acid analog having a tetrasubstituted C? carbon; and b) amino acid residues attached to the carboxy terminus of the base amino acid sequence, where the analogs have the properties indicated above. The invention also includes methods of treatment where these analogs are administered.

Abstract: The present disclosure relates in part to a flow field structure comprising a hydrophilic part and a hydrophobic part communicably attached to each other via a connecting interface. The present disclosure further relates to electrochemical cells comprising the aforementioned flow fields.